First major trial tests mpox vaccine in young children
NCT ID NCT06549530
Summary
This study is testing a vaccine called MVA-BN to see if it is safe and creates a strong immune response in children aged 2 to 12 years old, compared to adults. The goal is to prevent infections from mpox (monkeypox), smallpox, and related viruses. All participants receive two shots, four weeks apart, and researchers will track their antibody levels and any side effects for a year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONKEYPOX (MPOX) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Epicentre Mbarara Research Centre
Mbarara, Uganda
-
Uganda Virus Research Institute
Entebbe, Uganda
-
University of Kinshasa
Kinshasa, Democratic Republic of the Congo
Conditions
Explore the condition pages connected to this study.